UAS Labs Warning Letter
This article was originally published in The Tan Sheet
Executive Summary
Eden Prairie, Minn.-based firm must revise product labeling claims for its DDS-Plus non-dairy powder and capsules, according to a Warning Letter received by the firm following an FDA inspection of its facility in January. The district office singled out Internet claims for the probiotic supplements, including the statement "Bifidus bacteria may play a role in fighting colon cancer and reducing blood cholesterol." Statements touting Joint Formula Glucosamine/Chondroitin with Boswellia 8s MSM as a "natural approach to arthritis pain" also are cited. FDA says the statements render the products unapproved new drugs under the FD&C Act...
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.